Koninklijke Philips (PHIA) Q3 2025 earnings summary

Executive summary

• Q3 2025 saw 8% growth in comparable order intake and 3% comparable sales growth, with all business segments contributing and Personal Health showing particularly strong performance.

• Adjusted EBITA/EBITDA margin expanded by 50 basis points to 12.3%, driven by innovation, productivity, and disciplined execution despite ongoing tariff headwinds.

• Free cash flow rose to EUR 172 million, reflecting strong operational execution and productivity gains.

• Margin outlook for full-year 2025 is now expected at the upper end of the previously guided range.

• Innovation and cost management initiatives offset tariff impacts and supported margin improvement.

Financial highlights

• Group sales reached EUR 4.3 billion, with comparable sales growth of 3.3% year-over-year.

• Adjusted EBITA margin increased by 50 basis points to 12.3%; adjusted EBITDA margin at 17.2%.

• Net income rose to EUR 187 million, with adjusted diluted EPS from continued operations at EUR 0.36, up 13% year-over-year.

• Free cash flow in Q3 was EUR 172 million, a EUR 150 million improvement year-over-year.

• Ended Q3 with EUR 1.9 billion in cash and net debt of EUR 6.5 billion; leverage ratio stable at 2.2x net debt/adjusted EBITDA.

Outlook and guidance

• Full-year 2025 guidance reiterated: comparable sales growth of 1–3%, adjusted EBITA margin of 11.3–11.8% (now expected at the upper end), and free cash flow of EUR 0.2–0.4 billion.

• Tariff impact for 2025 anticipated at EUR 150–200 million after mitigation.

• Guidance excludes potential wider economic impacts and ongoing Respironics-related proceedings.

• Restructuring costs expected at ~120 bps for 2025, down from 150 bps last year.